Fax: (713) 563-2366
Breast conservation after neoadjuvant chemotherapy†
A prognostic index for clinical decision-making
Article first published online: 7 JAN 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 4, pages 689–695, 15 February 2005
How to Cite
Chen, A. M., Meric-Bernstam, F., Hunt, K. K., Thames, H. D., Outlaw, E. D., Strom, E. A., McNeese, M. D., Kuerer, H. M., Ross, M. I., Singletary, S. E., Ames, F. C., Feig, B. W., Sahin, A. A., Perkins, G. H., Babiera, G., Hortobagyi, G. N. and Buchholz, T. A. (2005), Breast conservation after neoadjuvant chemotherapy. Cancer, 103: 689–695. doi: 10.1002/cncr.20815
Presented at the 86th Annual Meeting of the American Radium Society, Napa Valley, California, May 1–5, 2004, where Allen M. Chen was the recipient of the Young Oncology Essay Award.
- Issue published online: 3 FEB 2005
- Article first published online: 7 JAN 2005
- Manuscript Accepted: 20 OCT 2004
- Manuscript Received: 12 OCT 2004
- Nellie B. Connally Breast Cancer Research Fund
- Arlette and William Coleman Foundation
- Stanford and Joan Alexander Foundation
- breast conservation;
- neoadjuvant chemotherapy;
- prognostic index;
- ipsilateral breast tumor
The appropriate selection criteria for breast-conserving therapy (BCT) after neoadjuvant chemotherapy are poorly defined. The purpose of the current report was to develop a prognostic index to help refine selection criteria and to serve as a general framework for clinical decision-making for patients treated by this multimodality approach.
From a group of 340 patients treated with BCT after neoadjuvant chemotherapy, the authors previously determined 4 statistically significant predictors of ipsilateral breast tumor recurrence (IBTR) and locoregional recurrence (LRR): clinical N2 or N3 disease, residual pathologic tumor size > than 2 cm, a multifocal pattern of residual disease, and lymphovascular space invasion in the specimen. The M. D. Anderson Prognostic Index (MDAPI) was developed by assigning scores of 0 (favorable) or 1 (unfavorable) for each of these 4 variables and using the total to give an overall MDAPI score of 0–4.
The MDAPI stratified the 340 patients into 3 subsets with statistically different levels of risk for IBTR and LRR after neoadjuvant chemotherapy and BCT. Actuarial 5-year IBTR-free survival rates were 97%, 88%, and 82% for patients in the low (MDAPI overall score 0 or 1, n = 276), intermediate (MDAPI score 2, n = 43), and high (MDAPI score 3 or 4, n = 12) risk groups, respectively (P < 0.001). Corresponding actuarial 5-year LRR-free survival rates were 94%, 83%, and 58%, respectively (P < 0.001).
Patients with an MDAPI score of 0 or 1, which made up 81% of the study population, had very low rates of IBTR and LRR. The MDAPI enabled the identification of a small group (4%) of patients who are at high risk for IBTR and LRR and who may benefit from alternative locoregional treatment strategies. Cancer 2005. © 2005 American Cancer Society.